ArticleWorld journal of otorhinolaryngology - head and neck surgery2026
TGF-β1 Induced Methylation to Regulate SOCS3 Expression in Abnormal Activation of Vocal Fold Fibroblasts.
Article in World journal of otorhinolaryngology - head and neck surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effect of TGF-β1 on vocal fold fibroblasts (VFFs) phenotype and the expression of DNA methyltransferase 1 (DNMT1), and to reveal the putative mechanism by which TGF-β1 regulates SOCS3 and its potential role in abnormal VFFs activation after vocal fold injury. Methods: The normal VFFs group (Control), injured VFFs group (Injured), normal VFFs+TGF-β1 group (Control+TGF-β1), and injured VFFs+TGF-β1 group (Injured+TGF-β1) were set, and 5-aza, a DNA methyltransferase inhibitor that reduces DNMT1 protein levels via covalent trapping and degradation, was added to block DNA methylation. Methylation-specific PCR (MSP) was used to detect the methylation level of the SOCS3 promoter. The methylation level of the SOCS3 promoter, and the protein and mRNA expressions of Type I collagen (COL1), α-smooth muscle actin (α-SMA), DNMT1, SOCS3, JAK2, and STAT3 were detected before and after the addition of TGF-β1 and 5-aza. Results: Compared to the Control group, the expressions of COL1, α-SMA, and DNMT1 were elevated in the Injured, Control+TGF-β1, and Injured+TGF-β1 groups. After 5-aza addition, no significant changes occurred in the Control group; however, the above markers were significantly decreased in the Injured, Control+TGF-β1, and Injured+TGF-β1 groups. The methylation level of the SOCS3 promoter was significantly increased, and SOCS3 expression was markedly downregulated in the Injured, Control+TGF-β1, and Injured+TGF-β1 groups, while the SOCS3 promoter was not significantly methylated in the Control group. After 5-aza addition, the methylation level of the SOCS3 promoter was significantly decreased in the Injured, Control+TGF-β1, and Injured+TGF-β1 groups, and concomitantly, SOCS3 mRNA and protein expression were significantly upregulated. The expressions of JAK2 and STAT3 were significantly increased in the Injured, Control+TGF-β1, and Injured+TGF-β1 groups, whereas a significant decrease was observed after adding 5-aza, with the changes positively correlated with SOCS3 upregulation. Conclusion: TGF-β1 is proposed to promote abnormal activation of VFFs, which may be associated with DNA methylation-mediated regulation of SOCS3. Specifically, TGF-β1 may downregulate SOCS3 expression via DNMT1-mediated promoter DNA methylation, and this process is speculated to participate in abnormal VFFs activation by relieving the inhibitory effect of SOCS3 on the JAK2/STAT3 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.